Cabergoline vs coasting for OHSS prevention
Treatments studied
Part of Women’s health & pregnancy clinical trials.
This study tests whether a medicine called cabergoline can lower the chance of ovarian hyperstimulation syndrome (OHSS) in women undergoing IVF who are at high risk. It compares cabergoline with a standard technique called 'coasting' (stopping fertility drugs for a few days).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 38 years old.
- Your body mass index (BMI) is under 30.
- You are using a long luteal protocol for ovarian stimulation.
- You have a high risk of ovarian hyperstimulation syndrome (OHSS) — meaning more than 20 large follicles or high estrogen levels early in your cycle.
- You do not have serious chronic medical conditions (like liver or kidney failure, uncontrolled high blood pressure or diabetes, or severe heart disease).
- You are not allergic to cabergoline.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a way to prevent a side effect called ovarian hyperstimulation syndrome (OHSS) in women with PCOS who are having ICSI (a type of IVF). The goal is to make fertility treatment safer for you.
This trial compares dydrogesterone with a GnRH antagonist to see which works better for women with a low number of eggs (poor responders) who are undergoing two rounds of egg retrieval in one cycle. It may help improve outcomes for those with specific fertility challenges.
This study tests if adding cabergoline to letrozole works better than letrozole alone to help women with PCOS ovulate. It may help participants who have not had success with standard treatments.
This study compares two methods of stimulating the ovaries before IVF: one using a standard hormone (hCG) and another using a different protocol. The goal is to see if the new method works as well as the standard one, while possibly being more cost-effective.
This trial tests a higher dose of the drug cabergoline to see if it works better for small prolactin-secreting tumors (microprolactinomas) in premenopausal women who have not been treated before. It aims to find a safe and effective way to lower high prolactin levels and shrink the tumor.
This trial compares two medications, cabergoline and bromocriptine, to see which works better for women with high prolactin levels (hyperprolactinemia). It aims to find a more effective treatment to help manage this condition, which can affect fertility and menstrual cycles.
Hear when a new Gynecologic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.